Pharmaceutical

Opinion: How the drug price negotiation program could a...

Prescription drug plans and drug manufacturers might not be thrilled with price ...

Group behind ProMED fires three top moderators amid strike

The organization that runs the infectious diseases surveillance system ProMED te...

Back to school for biotech, Biogen’s potential pivot, &...

Are there still too many biotech companies? How do you know when you're in a bub...

Trump surgeon general admits Trump White House made mis...

The Trump administration made some serious missteps during the coronavirus pande...

Biotech execs vie for a share of obesity drug boom: ‘It...

“We’re really just at the beginning of what’s going to be a very long journey in...

STAT+: Amazon’s chief medical officers on where the com...

“If we're going to do it, let's make sure we're leveraging things that Amazon do...

A new House health package & hospitals’ new site-neutra...

D.C. Diagnosis is STAT's twice-weekly newsletter about health care politics and ...

What could fix cancer clinical trials’ longstanding div...

When clinical trials lack diversity, that makes it difficult to understand how s...

NIH nominee Bertagnolli will get a confirmation hearing...

Monica Bertagnolli, Biden’s nominee to run the National Institutes of Health, wi...

STAT+: House transparency, PBM reform bill gains bipart...

A Democrat has signed on to a legislative package that would require health care...

How Seth Rogen and Lauren Miller Rogen are using comedy...

Since 2012, Lauren Miller Rogen and Seth Rogen have raised funds for at-home Alz...

STAT+: Lawsuit raises antitrust and kickback allegation...

Oncologists in Philadelphia are alleging Jefferson Health system is violating fe...

Obesity-related cardiovascular deaths tripled in the la...

Heart disease is killing fewer Americans overall, however, cardiovascular deaths...

STAT+: Pharmalittle: Novartis R&D hub’s name change ref...

Novartis is changing the name — and the guiding strategy — of its research and d...

AstraZeneca mulls risk strategy for Ultomiris following...

The US FDA has requested that AstraZeneca make modifications to the Ultomiris RE...

Idorsia reacquires aprocitentan rights from Janssen for...

Amid financial issues, Idorsia is hoping the resistant hypertension drug would b...